In Situ Self‐Assembly of Bispecific Peptide for Cancer Immunotherapy

Wang, Man‐Di; Lv, Gan-Tian; An, Hong‐Wei; Zhang, Ni-Yuan; Wang, Hao

doi:10.1002/anie.202113649

Cited by 59 publications

(37 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The designed nanoparticles showed good cytotoxicity and antitumor efficacy toward α v β 3 positive breast cancer cells and a 4T1-bearing mouse model [ 53 ]. In another recent study, Wang’s group reported a bispecific assembling peptide antiCD3-G7-RGD for tumor immunotherapy [ 54 ]. The RGD was used to improve tumor accumulation and cell internalization via the integrin receptor-mediated endocytosis process.…”

Section: Receptor-mediated Active Targeting Strategymentioning

confidence: 99%

Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies

et al. 2022

View full text Add to dashboard Cite

Poor targeting of therapeutics leading to severe adverse effects on normal tissues is considered one of the obstacles in cancer therapy. To help overcome this, nanoscale drug delivery systems have provided an alternative avenue for improving the therapeutic potential of various agents and bioactive molecules through the enhanced permeability and retention (EPR) effect. Nanosystems with cancer-targeted ligands can achieve effective delivery to the tumor cells utilizing cell surface-specific receptors, the tumor vasculature and antigens with high accuracy and affinity. Additionally, stimuli-responsive nanoplatforms have also been considered as a promising and effective targeting strategy against tumors, as these nanoplatforms maintain their stealth feature under normal conditions, but upon homing in on cancerous lesions or their microenvironment, are responsive and release their cargoes. In this review, we comprehensively summarize the field of active targeting drug delivery systems and a number of stimuli-responsive release studies in the context of emerging nanoplatform development, and also discuss how this knowledge can contribute to further improvements in clinical practice.

show abstract

Section: Receptor-mediated Active Targeting Strategymentioning

confidence: 99%

Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies

et al. 2022

View full text Add to dashboard Cite

show abstract

“…(B2) Chemical structure of a bispecific targeting peptide sequence composed of RGD for integrin αvβ3 binding, the antiCD3 sequence for CD3 binding, and self-assembly motif G7. Reproduced with permission from refs and . Copyright 2009 Elsevier and 2022 Wiley, respectively.…”

Section: Integrin-targeted Self-assemblymentioning

confidence: 99%

“…Later, scientists observed that the self-assembly of RGDcontaining peptide could induce integrin clustering. Following that, Wang and co-workers 78 designed Gly-Asn-Asn-Gln-Gln-Asn-Tyr-Arg-Gly-Asp (GNNQQNY-RGD), named G7-RGD, that bound with integrin αvβ3 (Figure 2B). The self-assembly of G7-RGD triggered the oligomerization of integrins on the membrane of breast cancer cells (MCF-7).…”

Section: ■ Integrin-targeted Self-assemblymentioning

confidence: 99%

Constructing ECM-like Structure on the Plasma Membrane via Peptide Assembly to Regulate the Cellular Response

Song

Zhang

et al. 2022

Langmuir

View full text Add to dashboard Cite

This feature article introduces the design of self-assembling peptides that serve as the basic building blocks for the construction of extracellular matrix (ECM)-like structure in the vicinity of the plasma membrane. By covalently conjugating a bioactive motif, such as membrane protein binding ligand or enzymatic responsive building block, with a self-assembling motif, especially the aromatic peptide, a self-assembling peptide that retains bioactivity is obtained. Instructed by the target membrane protein or enzyme, the bioactive peptides self-assemble into ECM-like structure exerting various stimuli to regulate the cellular response via intracellular signaling, especially mechanotransduction. By briefly summarizing the properties and applications (e.g., wound healing, controlling cell motility and cell fate) of these peptides, we intend to illustrate the basic requirements and promises of the peptide assembly as a true bottom-up approach in the construction of artificial ECM.

show abstract

“…At present, cell membrane-targeting fluorescent probes usually consist of a fluorophore and an anchoring element [ 15 ]. The cell membrane-anchoring element is generally the substance including: penetrating peptides [ 48 ], alkyl chains [ 49 ], cholesterol [ 50 ], protein ligands [ 51 ], antibodies, aptamers [ 52 ], etc. Protein ligands can be utilized to target cell membrane receptors; for example, a peptide sequence RGD often acts as a targeted peptide of the integrin receptor in the cell membrane.…”

Section: Design Strategies and Recent Examplesmentioning

confidence: 99%

AIEgen-Peptide Bioprobes for the Imaging of Organelles

et al. 2022

View full text Add to dashboard Cite

Organelles are important subsystems of cells. The damage and inactivation of organelles are closely related to the occurrence of diseases. Organelles’ functional activity can be observed by fluorescence molecular tools. Nowadays, a series of aggregation-induced emission (AIE) bioprobes with organelles-targeting ability have emerged, showing great potential in visualizing the interactions between probes and different organelles. Among them, AIE luminogen (AIEgen)-based peptide bioprobes have attracted more and more attention from researchers due to their good biocompatibility and photostability and abundant diversity. In this review, we summarize the progress of AIEgen-peptide bioprobes in targeting organelles, including the cell membrane, nucleus, mitochondria, lysosomes and endoplasmic reticulum, in recent years. The structural characteristics and biological applications of these bioprobes are discussed, and the development prospect of this field is forecasted. It is hoped that this review will provide guidance for the development of AIEgen-peptide bioprobes at the organelles level and provide a reference for related biomedical research.

show abstract

In Situ Self‐Assembly of Bispecific Peptide for Cancer Immunotherapy

Cited by 59 publications

References 32 publications

Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies

Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies

Constructing ECM-like Structure on the Plasma Membrane via Peptide Assembly to Regulate the Cellular Response

AIEgen-Peptide Bioprobes for the Imaging of Organelles

Contact Info

Product

Resources

About